NCT02188745: ER Reactivation Therapy for Breast Cancer

NCT02188745
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 90 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have ER+ tumor(s)
Exclusions: Patients with known unstable CNS disease- see trial for details
https://ClinicalTrials.gov/show/NCT02188745

Comments are closed.

Up ↑